NR4A1 and breast carcinoma: Hormonal receptor positive human epidermal receptor 2 negative (HR + /Her2−) comprises of approximately 60% of all BC [5], and multiple gene expression profiles are frequently used to evaluated the recurrence risk and benefit from adjuvant chemotherapy for HR + /Her2− early breast cancer (EBC) patients [6–8].